MK0524A Phase IIb Study (0524A-011)(COMPLETED)

Flushing Clinical Trial

Official title:
Part A: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of MK0524 Compared to Placebo Part B: A Dose-Ranging Study to Evaluate the Tolerability of MK0524 and Its Effects on Niacin-Induced Flushing in Lipid Clinic Patients

Status Completed

Clinical Trial Summary

Part A: This study will determine that MK0524 is well tolerated and does not effect lipids and blood glucose when given alone.

Part B: Determine dose ranges for MK0524 and MK0524 plus Niaspan(R) on the effects of lipids and blood glucose.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Flushing

Clinical Trial Details

NCT number	NCT00536237
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Completed
Phase	Phase 2
Start date	August 2004
Completion date	December 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00930839` - Role of Prostaglandins on Niacin-Induced Flushing	N/A
Completed	`NCT03370848` - Effects of Psyllium on Niacin Tolerability	Phase 4
Completed	`NCT03497442` - Treatment of Asian Flushing Syndrome With Topical Alpha Agonists	Early Phase 1
Completed	`NCT00895193` - Alternative Options to Minimize Niacin-Induced Flushing	N/A
Completed	`NCT00913081` - Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)	Phase 4
Completed	`NCT00533676` - Endpoint Validation Study (0524A-015)	Phase 2
Completed	`NCT00533611` - Effect of MK0524A on Flushing Caused by Niacin (0524A-056)	Phase 3